Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Equity Average (2016 - 2026)

United Therapeutics' Equity Average history spans 16 years, with the latest figure at $6.8 billion for Q4 2025.

  • On a quarterly basis, Equity Average rose 9.1% to $6.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 billion, a 9.1% increase, with the full-year FY2025 number at $6.8 billion, up 8.94% from a year prior.
  • Equity Average hit $6.8 billion in Q4 2025 for United Therapeutics, down from $6.9 billion in the prior quarter.
  • Over the last five years, Equity Average for UTHR hit a ceiling of $7.0 billion in Q2 2025 and a floor of $3.4 billion in Q1 2021.
  • Historically, Equity Average has averaged $5.2 billion across 5 years, with a median of $5.4 billion in 2023.
  • Biggest five-year swings in Equity Average: increased 4.76% in 2024 and later grew 26.69% in 2025.
  • Tracing UTHR's Equity Average over 5 years: stood at $3.9 billion in 2021, then grew by 20.16% to $4.7 billion in 2022, then grew by 24.98% to $5.8 billion in 2023, then increased by 7.25% to $6.3 billion in 2024, then rose by 9.1% to $6.8 billion in 2025.
  • Business Quant data shows Equity Average for UTHR at $6.8 billion in Q4 2025, $6.9 billion in Q3 2025, and $7.0 billion in Q2 2025.